팬젠

222110KOSDAQ의약품 제조업

52.8 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 18.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Panzen focuses on producing and selling biosimilar EPO drugs, offering CMO/CDO services, and developing biopharmaceuticals such as Factor VIII and Aflibercept. Its EPO product, approved in Malaysia, South Korea, the Philippines, Saudi Arabia, and Thailand, has expanded globally. The company's proprietary PanGen CHO-TECH™ technology enhances biopharmaceutical production efficiency through advanced cell line and process development.

Number of Employees

78people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

31.04Industry Average 11.930.0Point

2.6x industry avg (risky)

PBR

2.13Industry Average 0.890.0Point

2.4x industry avg (risky)

ROE

7.48Industry Average 4.015.5Point

1.9x industry avg (good)

Debt Ratio

0.10Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲85.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
팬젠, CDMO 영토 넓힌다…블록버스터급 세포주 3종 개발
팬젠이 혁신적인 세포주 개발로 바이오시밀러 시장 확장에 성공, 기술적 우위 확보로 긍정적 전망.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 4,710Won52-week high 7,34052-week low 4,555

1-month return0.0Point

1m -18.37% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항 (질병관리청 국립보건연구원 중증열성혈소판감소증후군(SFTS) 치료용 항체 비임상 시료 생산체계 고도화 및 평가과제 협상대상자 선정 )2026-05-27
Neutral분기보고서 (2026.03)2026-05-14